Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guizhounli Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guizhounli Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guizhounli Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Guizhounli Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guizhounli Pharmaceutical Co (SHSE:603439) has a FCF Margin % of 2.20% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Guizhounli Pharmaceutical Co and its competitors. This is 76% below median its historical median of 9.17. Over the past decade, Guizhounli Pharmaceutical Co's FCF Margin % has ranged from 1.83 to 14.43. According to the industry distribution chart, Guizhounli Pharmaceutical Co ranks #283 out of 963 companies in the Drug Manufacturers industry, placing it in the top 29.4%.
Is Guizhounli Pharmaceutical Co's FCF Margin % too high?
Guizhounli Pharmaceutical Co's current FCF Margin % of 2.20% is 76% below median its 10-year median of 9.17. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 14.43. The Drug Manufacturers industry median FCF Margin % is 2.55. Guizhounli Pharmaceutical Co's value of 2.20% is 13.7% below this industry median. Based on the distribution chart, Guizhounli Pharmaceutical Co ranks #283 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guizhounli Pharmaceutical Co ranks #283 out of 963 companies for FCF Margin %. This puts Guizhounli Pharmaceutical Co in the upper half of its industry. The industry median FCF Margin % is 2.55. Guizhounli Pharmaceutical Co's value of 2.20% is 13.7% below this benchmark. Historically, Guizhounli Pharmaceutical Co's own FCF Margin % has ranged from 1.83 to 14.43 over the past decade. While the company's 10-year median is 9.17 vs. the industry median of 2.55, Guizhounli Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.55, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhounli Pharmaceutical Co's current FCF Margin % of 2.20% is 13.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Guizhounli Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhounli Pharmaceutical Co's current FCF Margin % is 2.20%, which is 76% below median its own 10-year median of 9.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.70, compared to a current price of ¥11.14 — trading 24.2% below its estimated fair value. The current FCF Margin % is 2.20%, which is 76% below median its 10-year median of 9.17 and 13.7% below the Drug Manufacturers industry median of 2.55. Guizhounli Pharmaceutical Co's overall GF Score™ is 90/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current FCF Margin % is 2.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥11.14 is trading 24.2% below its estimated GF Value™ of ¥14.70.
GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603439:
FCF Margin %: 2.20% (76% below median its 10-year median of 9.17)
GF Value™: ¥14.70 vs. price of ¥11.14 (24.2% below fair value)
Industry Position: 13.7% below the Drug Manufacturers median (#283 of 963)
No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
90GF Score
Get the complete analysis for SHSE:603439
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603439 has been successfully added to your 
